Teneligliptin Decreases Uric Acid Levels by Reducing Xanthine Dehydrogenase Expression in White Adipose Tissue of Male Wistar Rats

Chihiro Moriya and Hiroaki Satoh

Department of Diabetology, Endocrinology, and Metabolism, Fukushima Medical University, 1 Hikarigaoka, Fukushima, Fukushima 960-1295, Japan

Correspondence should be addressed to Hiroaki Satoh; hiroakis-tky@umin.ac.jp

Received 1 May 2016; Revised 15 July 2016; Accepted 4 August 2016

Academic Editor: Ponnusamy Saravanan

Copyright © 2016 C. Moriya and H. Satoh. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

We investigated the effects of teneligliptin on uric acid metabolism in male Wistar rats and 3T3-L1 adipocytes. The rats were fed with a normal chow diet (NCD) or a 60% high-fat diet (HFD) with or without teneligliptin for 4 weeks. The plasma uric acid level was not significantly different between the control and teneligliptin groups under the NCD condition. However, the plasma uric acid level was significantly decreased in the HFD-fed teneligliptin treated rats compared to the HFD-fed control rats. The expression levels of xanthine dehydrogenase (Xdh) mRNA in liver and epididymal adipose tissue of NCD-fed rats were not altered by teneligliptin treatment. On the other hand, Xdh expression was reduced significantly in the epididymal adipose tissue of the HFD-fed teneligliptin treated rats compared with that of HFD-fed control rats, whereas Xdh expression in liver did not change significantly in either group. Furthermore, teneligliptin significantly decreased Xdh expression in 3T3-L1 adipocytes. DPP-4 treatment significantly increased Xdh expression in 3T3-L1 adipocytes. With DPP-4 pretreatment, teneligliptin significantly decreased Xdh mRNA expression compared to the DPP-4-treated 3T3-L1 adipocytes. In conclusion, our studies suggest that teneligliptin reduces uric acid levels by suppressing Xdh expression in epididymal adipose tissue of obese subjects.

1. Introduction

The prevalence of type 2 diabetes mellitus has increased dramatically worldwide, mainly because of changes in lifestyle, such as decreasing exercise and increasing high-fat diets. Obesity is the hallmark of the metabolic syndrome and represents a major global health problem that is frequently associated with the development of chronic diseases, including type 2 diabetes mellitus and cardiovascular disease [1]. A complex interorgan cross talk scenario between adipose tissue and other central and peripheral organs underlies the progression of these diseases, with adipose tissue on top of the cross talk hierarchy [2].

Use of dipeptidyl peptidase-4 (DPP-4) inhibitors is a strategy for glucose-lowering treatment in type 2 diabetic patients [3]. DPP-4 inhibitors were first approved for clinical use in 2006 with the DPP-4 inhibitor sitagliptin, and, thereafter, many other DPP-4 inhibitors have been introduced into clinical practice [4]. Teneligliptin, one of the DPP-4 inhibitors, has a unique structure characterized by five consecutive rings, which produce a potent and long-lasting effect [5, 6]. The gut-derived glucagon-like peptide-1 (GLP-1) plays important roles in both postprandial and long-term glucose homeostasis by increasing glucose-stimulated insulin secretion and inhibiting glucagon secretion [7]. DPP-4 is an enzyme that rapidly degrades circulating GLP-1, and, therefore, DPP-4 inhibitors prevent the inactivation of GLP-1 and, consequently, increase the circulating active GLP-1 levels above physiological levels that have antidiabetic actions [3]. In addition, DPP-4 is a ubiquitously expressed transmembrane glycoprotein that cleaves N-terminal dipeptides from a variety of substrates, including growth factors and hormones, neuropeptides, and chemokines, such as incretin hormones [8]. The expression of DPP-4 is substantially dysregulated in a variety of disease states, including inflammation, cancer, obesity, and diabetes [9]. It has also been reported that
DPP-4 released from adipose tissue is positively correlated with an increasing risk score for the metabolic syndrome. DPP-4 release is strongly correlated with adipocyte size, potentially representing an important source of DPP-4 in obesity. Therefore, it has been suggested that DPP-4 may be involved in linking adipose tissue and the metabolic syndrome [10].

Recently, it has been reported that adipose tissue produces and secretes uric acid through xanthine oxidoreductase (XOR) and that its production is enhanced in obesity [11]. Uric acid is also one of the risk factors for cardiovascular diseases [11, 12]. In mammals, XOR can exist in two enzymatic forms: xanthine dehydrogenase (XDH) and xanthine oxidase (XO). XO induces oxidative stress in the process of uric acid production. On the other hand, cardiac insufficiency and obesity produce a hypoxic state that leads to oxidative stress, which activates XO. Oxidative stress is highly relevant to aging and the development of various aging-related cardiovascular diseases and insulin resistance. Thus, inhibition of XO suppresses the oxidative stress of uric acid, which improves vascular endothelial dysfunction, heart failure, and insulin resistance [12].

We hypothesized that teneligliptin might have pleotropic effects in these tissues. DPP-4 inhibitors can improve glycemic control by prolonging the effect of GLP-1. Many studies have already reported that teneligliptin improves not only glucose but also the lipid profile and early-phase insulin secretion [13–17].

In the current study, the effect of teneligliptin on uric acid metabolism was examined in male Wistar rats. It was found that teneligliptin decreased uric acid levels in high-fat diet (HFD-) fed rats, but not normal chow diet- (NCD-) fed rats.

2. Methods

2.1. Materials. Teneligliptin was donated by Mitsubishi Tanabe Pharma Corporation (Osaka, Japan). 3T3-L1 preadipocytes were purchased from American Type Cell Collection (Manassas, VA, USA). Male Wistar rats were obtained from Charles River Laboratory Japan, Inc. (Kanagawa, Japan). The high-fat diet (HFD) (60% w/w, #D12492) was purchased from Research Diet Inc. (New Brunswick, NJ, USA). Isoflurane was purchased from Intervet K.K. (Tokyo, Japan). Pentobarbital was purchased from Kyoritsu Pharmaceutical Co. (Tokyo, Japan). DMEM, streptomycin, trypsin, fetal bovine serum (FBS), and TRIzol reagent were from Invitrogen Life Technologies (Carlsbad, CA, USA). The RNeasy kit was obtained from QIAGEN Inc. (Valencia, CA, USA). Total RNA (1 μg) was reverse-transcribed with the iScript cDNA Synthesis Kit according to the manufacturer’s instructions. Total RNA was further purified using the RNEasy kit with RNase-free DNase I treatment according to the manufacturer’s instructions (Bio-Rad Laboratories, Inc.). Quantitative real-time PCR was performed with a Bio-Rad system using iQ SYBR Green Supermix and specific primer pairs (Table 1) selected with Primer Express software (Applied Biosystems). The relative mass of specific RNAs was calculated by the comparative cycle of threshold detection method according to the manufacturer’s instructions.

2.2. Animal Studies. Six-week-old male Wistar rats (Charles River Laboratory Japan, Inc.) were housed individually under controlled 12-hour light, 12-hour dark cycles and temperature conditions (25°C) and had free access to water and a NCD or 60% HFD (Research Diet, Inc.). The male Wistar rats were fed with NCD or HFD with or without teneligliptin (~4.0 mg/kg body weight/day) for 4 weeks. The rats received a fresh diet every 3 days, and food consumption rates and body weight gains were monitored every 3 days. After the indicated diet for 4 weeks, the rats were fasted for 6 hours and then anesthetized in an induction chamber with 3% isoflurane. Plasma samples were obtained in the presence of EDTA-Na from the aorta of rats, and they were then promptly euthanized with pentobarbital (180 mg/kg body weight). The epididymal adipose tissue and liver samples were dissected and immediately frozen in liquid nitrogen and stored at −80°C for subsequent analysis. All procedures were performed in accordance with the Guide for Care and Use of Laboratory Animals of the NIH and were approved by the Animal Subjects Committee of Fukushima Medical University, Japan.

2.3. Uric Acid Level Measurement. Plasma uric acid levels were analyzed by uricase POD methods in a private laboratory (SRL Laboratory, Tokyo, Japan) [18].

2.4. Cell Culture and Cell Treatment. Mouse 3T3-L1 cells were cultured and differentiated as described previously [19, 20]. Unless otherwise indicated, adipocytes were used 14 days after differentiation. After incubation in serum-free DMEM high glucose for 3 hours, differentiated 3T3-L1 adipocytes were treated with the indicated concentration of teneligliptin and/or 200 ng/mL DPP-4 for 1, 3, 6, or 12 hours before each assay.

2.5. Quantitative Real-Time Reverse-Transcription PCR Analysis. Total RNA samples were extracted from cells, epididymal adipose tissue, and liver samples with TRIzol reagent, and total RNA was further purified using the RNeasy kit with RNase-free DNase I treatment according to the manufacturer’s instructions. Total RNA (1 μg) was reverse-transcribed with the iScript cDNA Synthesis Kit according to the manufacturer’s instructions (Bio-Rad Laboratories, Inc.). Quantitative real-time PCR was performed with a Bio-Rad system using iQ SYBR Green Supermix and specific primer pairs (Table 1) selected with Primer Express software (Applied Biosystems). The relative mass of specific RNAs was calculated by the comparative cycle of threshold detection method according to the manufacturer’s instructions.

2.6. DPP-4 Activity Measurement. DPP-4 activity in tissue homogenates and plasma sample was determined using a DPP-4 Activity Fluorometric Assay Kit (BioVision Incorporated) according to the manufacturer’s instructions. Fluorescence intensity (excitation/emission = 360/460 nm) was measured every 10 minutes by Varioskan Flash 2.4 (Thermo Fisher Scientific K.K.).

2.7. Uric Acid Secretion Measurement. Uric acid in cultured medium of differentiated 3T3-L1 adipocytes with 10 μM teneligliptin and/or 200 ng/mL DPP-4 for 24 hours was
Table 1: Primers used for real-time RT-PCR.

| Target sequence | Primers          | Primer sequence          | Band size (bp) |
|-----------------|------------------|--------------------------|----------------|
| Mouse Xdh       | mXdh-2819-F      | 5'-GGATGCTAATCGCAGAATAC-3' | 120            |
|                 | mXdh-2938-R      | 5'-GCTTCTGGTTGAAGTGAGTC-3' |                |
| Rat Xdh         | rXdh-2579-F      | 5'-GAAGACTGGAGCTGATGAG-3'  | 124            |
|                 | rXdh-2702-R      | 5'-GGGGATCTTATAGGCGTTAT-3' |                |
| Cyclophilin A (Cph) | Cph-96-F  | 5'-CTCCTTTGAGCTGTTTGCA-3'  | 325            |
|                 | Cph-420-R        | 5'-CACACCAGCTGTTGCAC-3'   |                |

Table 2: Body weight, food intake, and fasting plasma glucose measurements in NCD-fed and HFD-fed rats.

|                     | Control | Teneligliptin | Control | Teneligliptin |
|---------------------|---------|---------------|---------|---------------|
| Number              | 10      | 9             | 9       | 9             |
| BW (g)              | 367.6 ± 6.9 | 355.8 ± 16.7  | 415.0 ± 10.3* | 432.3 ± 9.3*  |
| Food intake (g/day) | 24.9 ± 0.6 | 24.4 ± 0.7    | 20.3 ± 0.3 | 20.6 ± 0.3    |
| FPG (mg/dL)         | 158.0 ± 9.1 | 161.6 ± 9.1   | 163.0 ± 3.8 | 162.6 ± 2.8   |

Means ± SE.
BW, body weight; FPG, fasting plasma glucose.
* P < 0.05 versus the normal chow diet control rats.

3. Results

3.1. Overall Animal Characteristics. The effect of teneligliptin was examined in both NCD-fed and HFD-fed male Wistar rats. Table 2 shows some of the general characteristics of the teneligliptin and control groups at 4 weeks. In the NCD-fed rats, body weight, average daily food consumption, and fasting plasma glucose levels were not significantly different between the teneligliptin and the control groups. Compared with the control group, HFD feeding led to a significant increase in body weight but with no significant change in fasting plasma glucose levels. In the HFD-fed rats, body weight, average daily food consumption, and fasting plasma glucose levels were also not significantly different between the two groups.

3.2. Effects of Teneligliptin on Uric Acid Metabolism in Male Wistar Rats. In the NCD-fed rats, plasma uric acid levels were not significantly different between the teneligliptin and the control groups (Figure 1). Interestingly, in the HFD-fed rats, plasma uric acid levels were significantly decreased by 21% (from 0.34 ± 0.02 mg/dL to 0.27 ± 0.02 mg/dL; P < 0.05) in the teneligliptin group compared with the control group (Figure 1).

3.3. Effect of Teneligliptin on the Uric Acid Synthesis Gene (Xdh mRNA) in Liver and Epididymal Adipose Tissues of Male Wistar Rats. To explore the potential cellular mechanisms involved in the teneligliptin-induced decrease of plasma uric acid levels, quantitative real-time PCR analysis was performed on total RNA from epididymal adipose tissue and a liver sample in selected chow-fed rats. The expression level of xanthine dehydrogenase (Xdh), which is one of the key enzymes in the uric acid synthesis pathway, was measured.
Figure 2: Effects of teneligliptin on xanthine dehydrogenase (Xdh) in liver (a) and epididymal adipose tissues (b) of male Wistar rats. Total RNAs extracted from liver tissue and epididymal adipose tissue of the control group (◻: NCD-fed rats: n = 10, HFD-fed rats: n = 9) and the teneligliptin group (◼: NCD-fed rats: n = 9, HFD-fed rats: n = 9) were used for gene expression analysis of Xdh. Levels of Cph were used for normalization of sample loading. Data are the means ± SEM. Data are expressed relative to NCD-fed control values. **P < 0.01 versus control rats.

The expression of Xdh in liver tissue was not significantly altered by teneligliptin treatment under either NCD or HFD conditions (Figure 2(a)). On the other hand, the expression of Xdh in epididymal adipose tissue was reduced significantly by 32% (P < 0.01) in the HFD-fed teneligliptin treated rats compared to the HFD-fed control rats, whereas the expression of Xdh in epididymal adipose tissue did not change significantly in the NCD-fed control rats and the NCD-fed teneligliptin treated rats.

3.4. Effect of Teneligliptin on DPP-4 Activity in Plasma, Liver, and Epididymal Adipose Tissues of Male Wistar Rats. To evaluate the efficacy of teneligliptin in plasma, liver, and epididymal adipose tissues of male Wistar rats, the activity levels of DPP-4 were measured. The plasma DPP-4 activity was decreased significantly by more than 95% (P < 0.001) in both the NCD-fed and the HFD-fed teneligliptin groups compared to the NCD-fed and the HFD-fed control groups, respectively (Figure 3(a)). Moreover, the plasma DPP-4 activity was increased significantly by 17% (P < 0.05) in the NCD-fed control rats compared to the NCD-fed control rats (Figure 3(a)). The activity of DPP-4 in liver reduced significantly by 71% (P < 0.001) and 65% (P < 0.001) in the NCD-fed and the HFD-fed teneligliptin groups compared to the NCD-fed and the HFD-fed control groups, respectively (Figure 3(b)). On the other hand, the activity of DPP-4 in epididymal adipose tissues reduced significantly by 82% (P < 0.001) and 79% (P < 0.001) in the NCD-fed and the HFD-fed teneligliptin groups compared to the NCD-fed and the HFD-fed control groups, respectively (Figure 3(c)). Moreover, the activity of DPP-4 in epididymal adipose tissue was increased significantly by 64% (P < 0.05) in the HFD-fed control rats compared to the NCD-fed control rats (Figure 3(c)), whereas the activity of DPP-4 in liver did not change significantly between the NCD-fed and the HFD-fed control rats (Figure 3(b)).

3.5. Effects of Teneligliptin on Uric Acid Synthesis Gene (Xdh) in 3T3-L1 Adipocytes. Next, whether treatment with teneligliptin altered the expression of Xdh in 3T3-L1 adipocytes was investigated. Quantitative real-time RT-PCR was performed on total RNA from serum-starved 3T3-L1 adipocytes that were treated with or without teneligliptin (1, 5, and 10 μM) for 3 hours. As shown in Figure 4, teneligliptin significantly decreased the expression of Xdh by 45% (P < 0.01), 35% (P < 0.01), and 34% (P < 0.01) at 1, 5, and 10 μM concentrations, respectively, in 3T3-L1 adipocytes. Moreover, as shown in Figure 5, treatment for 12 hours with DPP-4 (200 ng/mL), a novel adipocytokine that impairs insulin sensitivity in an autocrine and paracrine fashion [10], significantly increased the expression of Xdh by 49% (P < 0.01), whereas DPP-4 treatment for 6 hours did not significantly change the expression of Xdh. With DPP-4 (200 ng/mL) pretreatment for 12 hours, teneligliptin significantly decreased the expression of Xdh by 19% (P < 0.05), 30% (P < 0.05), and 26% (P < 0.01) at 1, 5, and 10 μM concentrations, respectively, compared to the DPP-4-treated 3T3-L1 adipocytes (Figure 6).

3.6. Effects of Teneligliptin and DPP-4 on Uric Acid Secretion from 3T3-L1 Adipocytes. Finally, whether treatment with teneligliptin and DPP-4 altered the secretion of uric acid from 3T3-L1 adipocytes was investigated. Serum-starved 3T3-L1 adipocytes were treated without or with teneligliptin (10 μM) and/or DPP-4 (200 ng/mL). We examined uric acid secretion for 24 hours in the presence of the indicated concentration of teneligliptin or DPP-4. As shown in Figure 7, the presence of DPP-4 (200 ng/mL) significantly increased the accumulation...
of uric acid from 3T3-L1 adipocytes by 8% \( (P < 0.05) \) compared to the control. Furthermore, addition of teneligliptin (10 \( \mu \)M) significantly reduced the rates of both spontaneous and DPP-4 stimulated uric acid accumulation from 3T3-L1 adipocytes by 13% \( (P < 0.05) \) and 21% \( (P < 0.01) \) (Figure 7). The protein content of the cells was not significantly changed by treatment with teneligliptin and DPP-4.

4. Discussion

Teneligliptin, a novel, highly selective DPP-4 inhibitor, is an antidiabetic drug that improves glycemic control without causing weight gain or increasing hypoglycemic risk in patients with type 2 diabetes mellitus. Although the glycemic efficacy of teneligliptin is well known, the nonglycemic efficacy and mechanisms of teneligliptin are not well understood. In this study, under the HFD condition, but not under the NCD condition, teneligliptin decreased plasma uric acid levels by reducing Xdh expression in adipose tissue but not liver. In addition, in 3T3-L1 adipocytes, DPP-4 increased Xdh expression, and teneligliptin decreased DPP-4-induced Xdh expression. These findings raised the possibility that teneligliptin may decrease plasma uric acid levels by inhibiting DPP-4 activity in adipose tissue.

DPP-4 is ubiquitously expressed on numerous different cell types, including epithelial cells, fibroblasts, and leukocyte subsets. Mechanisms that regulate DPP-4 gene transcription and enzymatic activity are not fully understood. It has recently been reported that adipocytes released DPP-4 in a differentiation-dependent manner [10]. In addition, DPP-4 expression in adipose tissue was increased in obese compared to lean subjects, a fact that is reflected by the increased release of DPP-4 from adipose tissue explants of obese subjects compared with lean subjects [10]. Circulating DPP-4 concentrations were increased in obese subjects and correlated with parameters of the metabolic syndrome, such as body mass index, waist circumference, and plasma fasting insulin concentration [10]. Furthermore, DPP-4 exerted autocrine...
and paracrine effects and impaired insulin signaling [10]. Thus, DPP-4 is a novel adipocytokine and biomarker, and it is a potential link between obesity and the metabolic syndrome.

A central finding in the present study is that teneligliptin, one of the DPP-4 inhibitors, reduced plasma uric acid levels in HFD-fed rats by downregulation of Xdh expression in adipose tissue. This observation is strongly associated with the upregulation of DPP-4 expression and release in adipose tissue of obese subjects. Therefore, DPP-4 increases Xdh expression and teneligliptin decreases DPP-4-induced Xdh expression in 3T3-L1 adipocytes. DPP-4 stimulates Xdh expression, and then Xdh expression promotes the production of uric acid.

Hyperuricemia is a key risk factor for the development of gout, renal dysfunction, hypertension, dyslipidemia, diabetes, and obesity. Hyperuricemia occurs as a result of the increased uric acid production, impaired renal uric
acid excretion, or a combination of both [21]. Endogenous production of uric acid is mainly from the liver, intestines, and other tissues such as muscles, kidney, and vascular endothelium [22]. Recently, it has been reported that adipose tissue produces and secretes uric acid through XOR and that its production is enhanced in obesity [11]. In mammals, XOR can exist in two enzymatic forms: XDH and XO. The present results suggest that inhibition of Xdh expression in adipose tissue is important in the treatment of diabetes. Another study also suggested that knockdown of XOR promoted transcription of a PPARγ [23]. Oxidative stress associated with XO production through the process of uric acid damages fat cells and vascular endothelial cells. In addition, in 3T3-L1 adipocytes, uric acid increased monocyte chemotactic protein (MCP-1) gene expression, which induced macrophages and inflammation, and decreased the expression of adiponectin. In addition, adding an antioxidant agent suppresses this reaction [24]. Aggravation of insulin resistance by such cell inflammation would exacerbate sugar metabolism itself. In other words, hyperuricemia can be related to multiple risk factors for atherosclerosis caused by the fat tissue. Suppressing the uric acid level is very important in diabetes therapy, because the goal of diabetes treatment may be to reduce the complications.

In this study, the effects of uric acid inhibition in the adipose tissue are caused by inhibiting DPP-4; therefore, we supposed that these effects are DPP-4 inhibitors common effects. We have presumed that one of the reasons is that linagliptin suppresses XOR activity in 3T3L-1 adipocytes [25]. Although the report did not take into account the uric acid production amount in adipose tissue in the methods of XOR activity measuring, it could be interpreted as the amount of uric acid in all over the tissue was reduced by linagliptin. This is consistent with the results of the present study. The effect that teneligliptin has reduced the uric acid is considered class effect. We have assumed this effect does not depend on each DPP-4’s inhibition of own binding differences or its binding pocket. Sitagliptin is grouped into class 3 the same as teneligliptin, although sitagliptin increased the plasma uric acid level in humans [26]. Moreover, sitagliptin and linagliptin are the same nonpeptide bonds. Therefore, we suppose that similar effects may occur by performing the cell experiments using other DPP-4 inhibitors. Nevertheless, in animal experiments, we consider that the effect does not appear in other DPP-4 inhibitors, because of the differential transferability to adipose tissue. The amount of distribution of the other DPP-4 inhibitors in adipose tissue is very low compared to that of teneligliptin in 24 hours after drug administration. It is not detected in linagliptin, vildagliptin, and alogliptin after 24 hours [27–29]. In sitagliptin, drug concentration in adipose tissue was much lower than that of teneligliptin [30, 31]. Furthermore, in the present study, it was 12 hours later that the Xdh expression increased to its highest level after pretreatment with DPP-4 in 3T-3L1 adipocytes. Therefore, it is also important to maintain plasma concentrations of DPP-4 inhibitors. Teneligliptin can maintain plasma concentrations because of its terminal elimination half-life of 26.9 hours [5].

On the other hand, whereas the inhibition of DPP-4 activity by teneligliptin has been confirmed in liver and in adipose tissue of male Wister rats under both HFD and NCD conditions, Xdh mRNA expression in liver was not significantly changed. Although we do not know the precise mechanisms underlying these differences in experimental results in liver and adipose tissue, the possibility exists. (1) The liver is the organ that highly expresses DPP-4 compared to adipose tissue [32]. (2) The inhibition effect of DPP-4 activity by teneligliptin in liver attenuates less than those in adipose tissue. Therefore, we presume that the inhibition effect of Xdh expression by teneligliptin might differ according to the inhibition effect of DPP-4 activity.

However, we have presumed that there are at least two limitations in this study as follows: (1) The standard methods for the measurement of XOR and XO activity have not been established yet. The current method for the measurement of XOR or XO evaluates the amount of uric acid production in the sample tissue by adding xanthine. However, this current method cannot measure accurately XOR or XO activity because the abundant uric acid is contained in any tissue [33]. Therefore, we have measured the expression of Xdh mRNA in this study, even though the measurement of Xdh mRNA expression has the possibility to evaluate the inadequate uric acid metabolism. (2) Although the uric acid metabolism differs between humans and rat, we found that teneligliptin decreased the uric acid level since teneligliptin decreased the Xdh mRNA expression in adipose tissue of the HFD-fed rats and 3T3-L1 adipocytes.

In conclusion, the present data suggest that teneligliptin reduces uric acid levels by suppressing Xdh expression in epididymal adipose tissue of obese subjects. Therefore, teneligliptin is more effective for controlling blood glucose and hyperuricemia in patients with type 2 diabetes mellitus.

**Abbreviations**

- DPP-4: Dipeptidyl peptidase-4
- GLP-1: Glucagon-like peptide-1
- XOR: Xanthine oxidoreductase
- XO: Xanthine oxidase
- Xdh: Xanthine dehydrogenase
- HFD: High-fat diet
- NCD: Normal chow diet

**Competing Interests**

The authors declare that there are no competing interests regarding the publication of this paper.

**Authors’ Contributions**

All authors contributed to the interpretation of results and review of the manuscript. Chihiro Moriya conducted the experiments and data analysis; Chihiro Moriya and Hiroaki Satoh designed the experiments and wrote the manuscript.
Acknowledgments
The authors thank Atsuko Hashimoto and Hiroko Ohashi for their excellent technical assistance. This work was supported in part by a Grant-in-Aid Scientific Research (C) (16K09363) from the Ministry of Education, Culture, Sports, Science, and Technology (Hiroaki Satoh).

References
[1] K. E. Wellen and G. S. Hotamisligil, "Inflammation, stress, and diabetes," Journal of Clinical Investigation, vol. 115, no. 5, pp. 1111–1119, 2005.
[2] H. Sell, D. Dietze-Schroeder, and J. Eckel, "The adipocyte-myocyte axis in insulin resistance," Trends in Endocrinology and Metabolism, vol. 17, no. 10, pp. 416–422, 2006.
[3] B. Ahrén, "Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications," Diabetes Care, vol. 30, no. 6, pp. 1344–1350, 2007.
[4] X.-W. Chen, Z.-X. He, Z.-W. Zhou et al., "Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus," Clinical and Experimental Pharmacology and Physiology, vol. 42, no. 10, pp. 999–1024, 2015.
[5] Y. Nakamaru, Y. Hayashi, R. Ikegawa et al., "Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans," Xenobiotica, vol. 44, no. 3, pp. 242–253, 2014.
[6] M. Nabeno, F. Akahoshi, H. Kishida et al., "A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site," Biochemical and Biophysical Research Communications, vol. 434, no. 2, pp. 191–196, 2013.
[7] D. J. Drucker, "The role of gut hormones in glucose homeostasis," Journal of Clinical Investigation, vol. 117, no. 1, pp. 24–32, 2007.
[8] R. Yazbeck, G. S. Howarth, and C. A. Abbott, "Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?" Trends in Pharmacological Sciences, vol. 30, no. 11, pp. 600–607, 2009.
[9] D. Röhbrorn, N. Wronkowitz, and J. Eckel, "DPP4 in diabetes," Frontiers in Immunology, vol. 6, article 386, 2015.
[10] D. Lamers, S. Famulla, N. Wronkowitz et al., "Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome," Diabetes, vol. 60, no. 7, pp. 1917–1925, 2011.
[11] Y. Toshima, H. Nishizawa, Y. Todeno et al., "Uric acid secretion from adipose tissue and its increase in obesity," Journal of Biological Chemistry, vol. 288, no. 38, pp. 27138–27149, 2013.
[12] H. Tsuchi, S. Kinugawa, and S. Matsushima, "Oxidative stress and heart failure," American Journal of Physiology—Heart and Circulatory Physiology, vol. 301, no. 6, pp. H2181–H2190, 2011.
[13] W. Tsuchimochi, H. Ueno, E. Yamashita et al., "Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients," Endocrine Journal, vol. 62, no. 1, pp. 13–20, 2015.
[14] S. Tanaka, K. Suzuki, C. Aoki et al., "Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy," Diabetes Technology and Therapeutics, vol. 16, no. 12, pp. 840–845, 2014.
[15] H. Otsuki, T. Kosaka, K. Nakamura, F. Shimomura, Y. Kuwahara, and T. Tsukamoto, "Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes," International Urology and Nephrology, vol. 46, no. 2, pp. 427–432, 2014.
[16] M. Kusunoki, D. Sato, T. Nakamura et al., "DPP-4 inhibitor teneligliptin improves insulin resistance and serum lipid profile in Japanese patients with type 2 diabetes," Drug Research, vol. 65, no. 10, pp. 532–534, 2014.
[17] M. Go and K. Kadowaki, "Teneligliptin for the treatment of type 2 diabetes," Drugs of Today, vol. 49, no. 10, pp. 615–629, 2013.
[18] P. Fossati, L. Prencipe, and G. Berti, "Use of 3,5-dichloro-2-hydroxybenzenesulfonic acid/4-aminophenazone chromogen system in direct enzymic assay of uric acid in serum and urine," Clinical Chemistry, vol. 26, no. 2, pp. 227–231, 1980.
[19] A. Kudoh, H. Satoh, H. Hirai, and T. Watanabe, "Pioglitazone upregulates adiponectin receptor 2 in 3T3-L1 adipocytes," Life Sciences, vol. 88, no. 23–24, pp. 1055–1062, 2011.
[20] M. T. A. Nguyen, H. Satoh, S. Faveluykis et al., "JNK and tumor necrosis factor-α mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes," The Journal of Biological Chemistry, vol. 280, no. 42, pp. 35361–35371, 2005.
[21] J. Su, Y. Wei, M. Liu et al., "Anti-hyperuricemic and nephroprotective effects of Rhizoma Dioscorea septempilae extracts and its main component dioecin via regulation of mOAT1, mURAT1 and mOCT2 in hypertensive mice," Archives of Pharmacal Research, vol. 37, no. 10, pp. 1336–1344, 2014.
[22] K. Chaudhary, K. Malhotra, J. Sowers, and A. Aroor, "Uric acid—key ingredient in the recipe for cardiorenal metabolic syndrome," Cardiorenal Medicine, vol. 3, pp. 208–220, 2013.
[23] K. J. Cheung, I. Tzameli, P. Pissios et al., "Xanthine oxidoreductase is a regulator of adipogenesis and PPARγ activity," Cell Metabolism, vol. 5, no. 2, pp. 115–128, 2007.
[24] W. Baldwin, S. McRae, G. Marek et al., "Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome," Diabetes, vol. 60, no. 4, pp. 1258–1269, 2011.
[25] S.-I. Yamagishi, Y. Ishibashi, A. Ojima, T. Sugira, and T. Matsu, "Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity," International Journal of Cardiology, vol. 176, no. 2, pp. 550–552, 2014.
[26] A. Kubota, H. Maeda, A. Kanamori et al., "Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients," Journal of Clinical Medicine Research, vol. 4, no. 5, pp. 309–313, 2012.
[27] Trazenta® (linagliptin), Common Technical Document 2011 (Japanese), http://www.pmda.go.jp/drugs/2011/P201100128/300256000_22300AMX0053_I100_1.pdf.
[28] Equa® (vildagliptin), Common Technical Document, Novartis 2010 (Japanese), http://www.pmda.go.jp/drugs/2010/P201000008/30024200_22200AMX00233_I100_5.pdf.
[29] Nesina® (alogliptin), Common Technical Document, Takeda Pharmaceutical Company, 2010 (Japanese), http://www.pmda.go.jp/drugs/2010/P201000029/400256000_22300AMX00309_I100_2.pdf.
[30] Y. Nakamaru, F. Akahoshi, H. Iijima, N. Hisanaga, and T. Kume, "Tissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidase-4 inhibitors," Biopharmaceutics & Drug Disposition, vol. 37, no. 3, pp. 142–155, 2016.
[31] Januvia® (sitagliptin), Common Technical Document, Merck and Co, 2009 (Japanese), http://www.pmda.go.jp/drugs/2009/P200900043/630153000_2200AMX02257_I100_1.pdf.
[32] S. Mentzel, H. B. P. M. Dijkman, J. P. H. F. Van Son, R. A. P. Koene, and K. J. M. Assmann, “Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice,” *Journal of Histochemistry and Cytochemistry*, vol. 44, no. 5, pp. 445–461, 1996.

[33] T. Murase, M. Nampei, M. Oka et al., “Xanthine oxidoreductase activity assay in tissues using stable isotope-labeled substrate and liquid chromatography high-resolution mass spectrometry,” *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, vol. 1008, pp. 189–197, 2016.